(Page 2 of 3)
version of its GemCode platform for single-cell RNA sequencing at the J.P. Morgan Conference, saying it enables detailed gene-expression profiling on a cell-by-cell basis. San Diego’s Illumina launched a desktop MiniSeq Sequencing System, saying it enables a broad range of DNA and RNA sequencing applications.
—Immune Design (NASDAQ: IMDZ), based both in Seattle and South San Francisco, CA, said it has received orphan drug designation from the FDA for the two components of its treatment CMB305. Immune Design is currently in Phase 2 testing for soft tissue sarcoma, in combination with Genentech’s atezolizumab.
—Healthcare software maker Syapse of Palo Alto, CA, closed the first tranche of a $25 million Series C round led by the venture arm of health provider Ascension.
—Kodiak Sciences, the Palo Alto, CA-based biopharmaceutical developing new drugs for eye disease, said it has closed on a $34 million Series B financing round that was led by an unnamed U.S. life sciences investor. With the latest round, Kodiak has raised more than $60 million altogether.
—Two West Coast firms struck oncology deals, but didn’t divulge financial details. San Francisco’s Gritstone Oncology said it would license intellectual property, tools, and data from Memorial Sloan Kettering Cancer Center in New York. Seattle’s Adaptive Biotechnologies said it would team up with … Next Page »